Clinical Trials Browser

Interventional × onvansertib × 1 year × Clear all

Pancreatic Neoplasms

NCT05549661 2026-02-23

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Phase 1/2 Active not recruiting

50 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06106308 2026-01-12

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Phase 2 Active not recruiting

113 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05450965 2025-12-17

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Phase 2 Recruiting

37 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Clinical Trials

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Onvansertib + Paclitaxel In TNBC

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer